Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06310564 |
TitleLow and Intermediate Risk oliGometastatic coloREctal cancEr patieNts Treated With Stereotactic ABlative Radiotherapy | Phase
Not Applicable
|
Date Added 2024-03-15 |
Location
Italy
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06336902 |
TitleBotensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2024-03-29 |
Location
California, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Balstilimab, Botensilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT03658785 |
TitleImmunotherapy for the Treatment of Advanced Solid Tumor | Phase
Phase 1
|
Date Added 2018-09-05 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Aldesleukin, Cyclophosphamide, Fludarabine, TIL |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04262687 |
TitleChemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate | Phase
Phase 2
|
Date Added 2020-02-10 |
Location
France
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Bevacizumab, capecitabine, oxaliplatin, Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT03692429 |
TitlealloSHRINK – Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | Phase
Phase 1
|
Date Added 2018-10-02 |
Location
Florida, United States
Belgium |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
CYAD-101, FOLFIRI, FOLFOX |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03940820 |
TitleClinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors | Phase
Phase 1/Phase 2
|
Date Added 2019-05-07 |
Location
China
|
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
ROBO1 CAR-NK cells |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03874897 |
TitleChimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors. | Phase
Phase 1
|
Date Added 2019-03-14 |
Location
China
|
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
CAR-CLDN18.2 T-Cells, Chemotherapy, PD-1 Monoclonal Antibody |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03745326 |
TitleAdministering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | Phase
Phase 1, Phase 2
|
Date Added 2018-11-19 |
Location
Maryland, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Aldesleukin, anti-KRAS G12D mTCR PBL, Cyclophosphamide, Fludarabine |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03280511 |
TitleAdjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients | Phase
Phase 2
|
Date Added 2017-09-12 |
Location
Denmark
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
PIPAC |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05141474 |
TitleAssessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors | Phase
Early Phase 1
|
Date Added 2021-12-02 |
Location
Spain
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Interleukin-2, NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
